Combination of Immune checkpoint inhibitors and vaccine in glioma stem cell
| Project/Area Number |
15K10327
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
松田 真秀 筑波大学, 医学医療系, 講師 (30614333)
坪井 康次 筑波大学, 医学医療系, 教授 (90188615)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | glioma / immunotherapy / immune checkpoint / glioma stem cell / 免疫療法 / 悪性神経膠腫 / グリオーマ / 免疫チェックポイント分子 / 脳腫瘍 / 神経膠腫 / PD-1 / PD-L1 / 脳腫瘍学 |
|---|
| Outline of Final Research Achievements |
This study was designed to clarify the change of the molecular expression, including programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), on the initial and secondary resected glioblastoma (GBM) specimens and to address the influence of these expressions for patient outcome after second surgery of glioblastoma. We investigated 16 GBM patients treated with radiotherapy and temozolomide. Four patients who were treated with immunotherapy using autologous formalin-fixed tumor vaccine were enrolled. Patients with high PD-1 expression of secondary specimen had bad prognosis after secondary resection. Similar result was seen also in PD-L1 expression. PD-1/PD-L1 pathway may be associated with patient outcome after second surgery of glioblastoma. Next, vitro and vivo study using induced murine glioma stem cell showed chemodrug and/or interferon gumma enhanced PD-1/PD-L1 pathway.
|
Report
(4 results)
Research Products
(10 results)
-
-
-
-
-
-
-
-
[Presentation] Multicenter randomized placebo-controlled trial of autologous formalin-fixed tumor vaccine for newly-diagnosed glioblastomas2017
Author(s)
2.Muragaki Y, Maruyama T, Ishikawa E, Nitta M, Ikuta S, Tsuboi K, Matsumura A, Nakamura H, Abe T, Saito R, Tabei Y, Arakawa Y, Momii Y, Matsutani M, Karasawa K, Nakazato Y, Ohno T, Maebayashi K
Organizer
SNO2017
Related Report
Int'l Joint Research
-
-
